China nih a ser mi covid runvennak sii Sinopharm cu a tha a der deuh ruangah sii a chunhmi hna nih a voihnihnak ah booster dose voikhat chunh chih a herh tiah mithiam pawl nih an chim.

Hi China sii a hmang mi Peru ram ah zohfelnak an tuahmi data ningah sii voihnih a chunh mi nih zawtnak 50.4% lawng a ven khawh caah zawtnak doh khawhnak ding ahcun duh ning in a cak lo tiah South America ngandamnak vuanci zung nih an thanh. Cucaah, mithiam pawl nih sinopharm vaccine dose 2 lak hnuah booster dose voikhat lak hi ruah a herh ngai tiah an ruah.Amah belte cu mah vaccine nih thih khawhnak chance 94% hrawngin a khamh khawh ve tiah an ti.

Peru ram National Health Institute le Institute dang pahnih in mithaim hna nih China, Beijing Institute of Biological Products nih a ser mi Sinopharm (BBIBP-CorV ) sii hi voihmih a chun cang mi Frontline workers sing 4 hna sin in zohfel mi a si. Peru ngandamnak lei riantuan hna nih Sinopharm sii lawng hi an ram ah an hman mi a si i, a ruang cu mah sii hi an ram ah a phanh hmasa cem a si ruangah a si i, atu cu AstraZeneca le Pfizer zong an chunh khawh ve cang tiah theih a si.

Sinopharm sii a chun cang mi Cambodia, UAE le ram cheukhat hna cu US le UK sii he booster dose voikhat pek dingin chimh an si. Peru health institute in Dr. Leli Solari nih; a tha cem mi cu a voithumnak sii i chunh a herh hrimhrim ti hi a si. A voithumnak hi zeitik ah dah chunh ding a si lai i, zei vaccine dah kan hman lai ti hi a si tiah a chim.

Sinopharm hi 50.4% lawng zawtnak a ven khawh mi cu a tha a der deuh tiah ruah a si nain WHO nih a pom cang mi a si i, doh khawhnak level 50% a si ahcun a pom mi a si. WHO nih China nih covid sii a ser mi hi zohfelnak an ngeih hmasa bik ahcun 78.1% in zawtnak a do khawhmi a si tiah a chim. Credit: The Chin Post